Adamas Consulting Brochure
download PDF - English 177k
download PDF - Japanese 177k

Due Diligence

Pharmaceutical companies are facing increasing financial pressures to produce an acceptable return on investment (ROI).

The cost of drug development is increasing and the level of R&D productivity has declined. At the same time companies are facing cost containment measures by their payors.

Loss of patent rights for the larger selling pharmaceutical selling products adds financial pressure.

One of the many strategic options that pharmaceutical companies are adopting is to fill their R&D pipeline with in-licensed compounds from other companies.

Part of the process of in-licensing compounds is to manage the inherent risk. Increasingly, companies that in-license compounds that are under clinical development want to manage the risk by understanding more fully the clinical programme. Are the current programmes robust? Will any of the programmes need to be repeated?

ADAMAS has the team, the experience, the skills and the competencies to conduct independent due diligence of a clinical development programme to help companies understand and manage the associated risk.

Contact ADAMAS Consulting by email or on +44 (0)1344 751 210 to discuss your individual requirements.

“As always, it was a very interesting and enriching experience auditing with you; I really enjoyed our collaboration.“H.B., CQA Manager, Global Pharma